Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 9

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 9
---
 by Nucana plc

Pursuant to 17 C.F.R. Section 200.83

Foreign private issuers are also exempt from certain more stringent executive compensation
disclosure rules. Thus, if we remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are not a foreign private issuer. As a consequence, we do not know if some
investors will find our ADSs less attractive, which may result in a less active trading market for our ADSs or more volatility in the price of our ADSs.

3

Confidential Treatment Requested by Nucana plc Pursuant to 17 C.F.R. Section 200.83

THE OFFERING

| ADSs offered by us | Up to     ADSs, each representing twenty-five ordinary shares, based on an assumed combined public offering price of $   per ADS and accompanying Series A Warrant and Series B Warrant, which is the last 
 reported sale price of our ADSs on The Nasdaq Capital Market on     , 2025.                                                                                                                                |

| Pre-Funded Warrants offered by us | We are also offering to those purchasers, if any, whose purchase of the ADSs in this offering would result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or at the election of 
 the purchaser, 9.99%) of our outstanding ADSs immediately following consummation of this offering, the opportunity to purchase, if they so choose, Pre-Funded Warrants in lieu of the ADSs that would otherwise                                    
 result in ownership in excess of 4.99% (or 9.99%, as applicable) of our ADSs.                                                                                                                                                                      |

| The purchase price of each Pre-Funded Warrant and accompanying Warrants will equal the price per ADS and accompanying Warrants being sold to the public in this offering, minus 
 $  , and the exercise price of each Pre-Funded Warrant will be $  per share.                                                                                                    |

| Each Pre-Funded Warrant will be immediately exercisable and may be exercised at any time until exercised in full. There is no expiration date for the Pre-Funded Warrants. There is no established trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for a